Johnson & Johnson has agreed to pay $2.2 billion to settle probes by the U.S. government of its marketing of Risperdal and other medications, the second-largest settlement of its kind in history. Additional cases with individual states are ongoing, for which J&J is setting aside an additional $600 million.
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.